The possible role furin and furin inhibitors in endometrial adenocarcinoma: A narrative review.
endometrial adenocarcinoma
furin
inflammatory signaling
invasion
metastasis
proliferation
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
revised:
29
09
2023
received:
02
08
2023
accepted:
09
10
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
aheadofprint
Résumé
Endometrial adenocarcinoma (EAC) is a malignant tumor of the endometrium. EAC is the most common female malignancy following the menopause period. About 40% of patients with EAC are linked with obesity and interrelated with hypertension, diabetes mellitus, and high circulating estrogen levels. Proprotein convertase (PC) furin was involved in the progression of EAC. Furin is a protease enzyme belonging to the subtilisin PC family called PC subtilisin/kexin type 3 that converts precursor proteins to biologically active forms and products. Aberrant activation of furin promotes abnormal cell proliferation and the development of cancer. Furin promotes angiogenesis, malignant cell proliferation, and tissue invasion by malignant cells through its pro-metastatic and oncogenic activities. Furin activity is correlated with the malignant proliferation of EAC. Higher expression of furin may increase the development of EAC through overexpression of pro-renin receptors and disintegrin and metalloprotease 17 (ADAM17). As well, inflammatory signaling in EAC promotes the expression of furin with further propagation of malignant transformation. Furin is associated with the development and progression of EAC through the induction of proliferation, invasion, and metastasis of malignant cells of EAC. Furin induces ontogenesis in EAC through activation expression of ADAM17, pro-renin receptor, CD109, and TGF-β. As well, EAC-mediated inflammation promotes the expression of furin with further propagation of neoplastic growth and invasion.
Sections du résumé
BACKGROUND
BACKGROUND
Endometrial adenocarcinoma (EAC) is a malignant tumor of the endometrium. EAC is the most common female malignancy following the menopause period. About 40% of patients with EAC are linked with obesity and interrelated with hypertension, diabetes mellitus, and high circulating estrogen levels. Proprotein convertase (PC) furin was involved in the progression of EAC.
RECENT FINDINGS
RESULTS
Furin is a protease enzyme belonging to the subtilisin PC family called PC subtilisin/kexin type 3 that converts precursor proteins to biologically active forms and products. Aberrant activation of furin promotes abnormal cell proliferation and the development of cancer. Furin promotes angiogenesis, malignant cell proliferation, and tissue invasion by malignant cells through its pro-metastatic and oncogenic activities. Furin activity is correlated with the malignant proliferation of EAC. Higher expression of furin may increase the development of EAC through overexpression of pro-renin receptors and disintegrin and metalloprotease 17 (ADAM17). As well, inflammatory signaling in EAC promotes the expression of furin with further propagation of malignant transformation.
CONCLUSION
CONCLUSIONS
Furin is associated with the development and progression of EAC through the induction of proliferation, invasion, and metastasis of malignant cells of EAC. Furin induces ontogenesis in EAC through activation expression of ADAM17, pro-renin receptor, CD109, and TGF-β. As well, EAC-mediated inflammation promotes the expression of furin with further propagation of neoplastic growth and invasion.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1920Subventions
Organisme : University of Witten-Herdecke Germany
Informations de copyright
© 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Horn L-C, Höhn AK, Krücken I, Stiller M, Obeck U, Brambs CE. Mesonephric-like adenocarcinomas of the uterine corpus: report of a case series and review of the literature indicating poor prognosis for this subtype of endometrial adenocarcinoma. J Cancer Res Clin Oncol. 2020;146(4):971-983.
Batiha GE-S, Gari A, Elshony N, et al. Hypertension and its management in COVID-19 patients: the assorted view. Int J Cardiol Cardiovasc Risk Prev. 2021;11:200121.
Kölbl AC, Schlenk K, Behrendt N, Andergassen U. The importance of hCG in human endometrial adenocarcinoma and brleast cancer. Int J Biol Markers. 2018;33(1):33-39.
Kit OI, Frantsiyants EM, Bandovkina VA, et al. Modifying effect of obesity on the content of sex hormones and their receptors in endometrial adenocarcinoma and its surrounding tissue. Cardiometry. 2022;21:34-40.
Alexa M, Hasenburg A, Battista MJ. The TCGA molecular classification of endometrial cancer and its possible impact on adjuvant treatment decisions. Cancers. 2021;13(6):1478.
Goulder A, Gaillard SL. Molecular classification of endometrial cancer: entering an era of precision medicine. J Gynecol Oncol. 2022;33(3):e47.
Shreffler J, Huecker MR. Diagnostic Testing Accuracy: Sensitivity, Specificity, Predictive Values and Likelihood Ratios. StatPearls Publishing; 2020.
Shreffler J, Huecker MR. Diagnostic Testing Accuracy: Sensitivity, Specificity, Predictive Values and Likelihood Ratios. StatPearls Publishing; 2022.
Rižner TL. Discovery of biomarkers for endometrial cancer: current status and prospects. Expert Rev Mol Diagn. 2016;16(12):1315-1336.
Jaaks P, Bernasconi M. The proprotein convertase furin in tumour progression. Int J Cancer. 2017;141(4):654-663.
Singh H, Heng S, Nicholls PK, et al. Proprotein convertases in post-menopausal endometrial cancer: distinctive regulation and non-invasive diagnosis. Biochem Biophys Res Commun. 2012;419(4):809-814.
Heng S, Stephens AN, Jobling TW, Nie G. Total PC activity is increased in uterine lavage of post-menopausal endometrial but not ovarian cancer patients. J Cancer. 2016;7(13):1812-1814.
Basak A, Chen A, Scamuffa N, Mohottalage D, Basak S, Khatib A-M. Blockade of furin activity and furin-induced tumor cells malignant phenotypes by the chemically synthesized human furin prodomain. Curr Med Chem. 2010;17(21):2214-2221.
Braun E, Sauter D. Furin-mediated protein processing in infectious diseases and cancer. Clin Transl Immunol. 2019;8(8):e1073.
Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood. 2008;111(2):924-931.
Alsubaie N, Al-kuraishy HM, Al-Gareeb AI, et al. Statins use in Alzheimer disease: bane or boon from frantic search and narrative review. Brain Sci. 2022;12(10):1290.
Al-kuraishy HM, Al-Gareeb AI, Alkazmi L, Habotta OA, Batiha GE-S. High-mobility group box 1 (HMGB1) in COVID-19: extrapolation of dangerous liaisons. Inflammopharmacology. 2022;30:1-10.
Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol. 2002;3(10):753-766.
Saad HM, Tourky GF, Al-kuraishy HM, et al. The potential role of MUC16 (CA125) biomarker in lung cancer: a magic biomarker but with adversity. Diagnostics. 2022;12(12):2985.
Fernandez C, Rysä J, Almgren P, et al. Plasma levels of the proprotein convertase furin and incidence of diabetes and mortality. J Intern Med. 2018;284(4):377-387.
Hussien NR, Al-Naimi MS, Rasheed HA, Al-kuraishy HM, Al-Gareeb AI. Sulfonylurea and neuroprotection: the bright side of the moon. J Adv Pharm Technol Res. 2018;9(4):120-123.
Seidah NG, Khatib AM, Prat A. The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol Chem. 2006;387(7):871-877.
Jin W, Wang X, Millar JS, et al. Hepatic proprotein convertases modulate HDL metabolism. Cell Metab. 2007;6(2):129-136.
Rasheed HA, Al-kuraishy HM, Al-Gareeb AI, Hussien NR, Al-Nami MS. Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: bane or boon. J Adv Pharm Technol Res. 2019;10(4):163-168.
Coppola I, Brouwers B, Meulemans S, Ramos-Molina B, Creemers JW. Differential effects of furin deficiency on insulin receptor processing and glucose control in liver and pancreatic β cells of mice. Int J Mol Sci. 2021;22(12):6344.
Harlid S, Myte R, Van Guelpen B. The metabolic syndrome, inflammation, and colorectal cancer risk: an evaluation of large panels of plasma protein markers using repeated, prediagnostic samples. Mediators Inflamm. 2017;2017:1-9.
Li N, Luo W, Juhong Z, et al. Associations between genetic variations in the FURIN gene and hypertension. BMC Med Genet. 2010;11(1):1-7.
He Y, Ren L, Zhang Q, et al. Serum furin as a biomarker of high blood pressure: findings from a longitudinal study in Chinese adults. Hypertens Res. 2019;42(11):1808-1815.
He Y, Ren L, Zhang Q, et al. Deficient serum furin predicts risk of abdominal obesity: findings from a prospective cohort of Chinese adults. Postgrad Med J. 2021;97(1146):234-238.
Heng S, Stephens AN, Jobling TW, Nie G. Measuring PC activity in endocervical swab may provide a simple and non-invasive method to detect endometrial cancer in post-menopausal women. Oncotarget. 2016;7(29):46573-46578.
Al-Nami MS, Al-kuraishy HM, Al-Gareeb AI, Al-Mamoori F. Metabolic profile and prolactin serum levels in men with type 2 diabetes mellitus: old-new rubric. Int J Crit Illn Inj Sci. 2019;9(3):120-126.
Ren K, Jiang T, Zheng X-L, Zhao G-J. Proprotein convertase furin/PCSK3 and atherosclerosis: new insights and potential therapeutic targets. Atherosclerosis. 2017;262:163-170.
Abe SK, Inoue M. Green tea and cancer and cardiometabolic diseases: a review of the current epidemiological evidence. Eur J Clin Nutr. 2021;75(6):865-876.
MacKintosh ML, Crosbie EJ. Prevention strategies in endometrial carcinoma. Curr Oncol Rep. 2018;20:1-8.
Tzenios N, Chahine M, Tazanios M. Obesity and endometrial cancer: the role insulin resistance and adipokines. Spec J Med Acad Other Life Sci. 2023;1(2). doi:10.58676/sjmas.v1i2.12
Sacerdote C, Ricceri F. Epidemiological dimensions of the association between type 2 diabetes and cancer: a review of observational studies. Diabetes Res Clin Pract. 2018;143:369-377.
Chu D, Wu J, Wang K, et al. Effect of metformin use on the risk and prognosis of endometrial cancer: a systematic review and meta-analysis. BMC Cancer. 2018;18(1):1-11.
Njoku K, Abiola J, Russell J, Crosbie EJ. Endometrial cancer prevention in high-risk women. Best Pract Res Clin Obstet Gynaecol. 2020;65:66-78.
Ding S, Madu CO, Lu Y. The impact of hormonal imbalances associated with obesity on the incidence of endometrial cancer in postmenopausal women. J Cancer. 2020;11(18):5456-5465.
He Z, Khatib A-M, Creemers JW. The proprotein convertase furin in cancer: more than an oncogene. Oncogene. 2022;41(9):1252-1262.
McMahon S, Grondin F, McDonald PP, Richard DE, Dubois CM. Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J Biol Chem. 2005;280(8):6561-6569.
Niland S, Riscanevo AX, Eble JA. Matrix metalloproteinases shape the tumor microenvironment in cancer progression. Int J Mol Sci. 2021;23(1):146.
Castro F, Cardoso AP, Gonçalves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9:847.
Hipp MM, Shepherd D, Gileadi U, et al. Processing of human toll-like receptor 7 by furin-like proprotein convertases is required for its accumulation and activity in endosomes. Immunity. 2013;39(4):711-721.
He Z, Khatib A-M, Creemers JW. Loss of the proprotein convertase Furin in T cells represses mammary tumorigenesis in oncogene-driven triple negative breast cancer. Cancer Lett. 2020;484:40-49.
He Z, Thorrez L, Siegfried G, et al. The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer. Oncogene. 2020;39(17):3571-3587.
Page RE, Klein-Szanto AJ, Litwin S, et al. Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Anal Cell Pathol. 2007;29(4):289-299.
Chen C, Gupta P, Parashar D, et al. ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis. Oncogene. 2020;39(14):2921-2933.
Ahmed BS, Aljebori HA, Al-sudani IM. MicroRNAs 301a and 93 biomarkers for endometrial cancer. Indian J Public Health Res Dev. 2019;10(2):740.
Bassi DE, Mahloogi H, De Cicco RL, Klein-Szanto A. Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol. 2003;162(2):439-447.
Dawood SA, Jwad MA, Hussaini HA. A comparison between the effect of vaginal sildenafil versus oral estradiol valerate on ultrasound parameters of endometrial receptivity and follicular growth in Iraqi females receiving letrozole for induction of ovulation. Iraqi J Embryos Infertil Res. 2020;10(1):35-50.
Ke JY, Yang J, Li J, Xu Z, Li MQ, Zhu ZL. Baicalein inhibits FURIN-MT1-MMP-mediated invasion of ectopic endometrial stromal cells in endometriosis possibly by reducing the secretion of TGFB1. Am J Reprod Immunol. 2021;85(3):e13344.
Zakrzewski PK. Canonical TGFβ signaling and its contribution to endometrial cancer development and progression-underestimated target of anticancer strategies. J Clin Med. 2021;10(17):3900.
Dubois CM, Blanchette F, Laprise M-H, Leduc R, Grondin F, Seidah NG. Evidence that furin is an authentic transforming growth factor-β1-converting enzyme. Am J Pathol. 2001;158(1):305-316.
Bernot D, Stalin J, Stocker P, et al. Plasminogen activator inhibitor 1 is an intracellular inhibitor of furin proprotein convertase. J Cell Sci. 2011;124(8):1224-1230.
Batiha GE-S, Al-kuraishy HM, Al-Maiahy TJ, et al. Plasminogen activator inhibitor 1 and gestational diabetes: the causal relationship. Diabetol Metab Syndr. 2022;14(1):127. doi:10.1186/s13098-022-00900-2
Lin L-L, Kost ER, Lin C-L, et al. PAI-1-dependent inactivation of SMAD4-modulated junction and adhesion complex in obese endometrial cancer. Cell Rep. 2020;33(2):108253.
Al-kuraishy HM, Al-Gareeb AI, Al-Harcan NAH, Alexiou A, Batiha G. Tranexamic acid and plasminogen/plasmin glaring paradox in COVID-19. Endocr Metab Immune Disord Drug Targets. 2023;23(1):35-45.
Hagiwara S, Murakumo Y, Mii S, et al. Processing of CD109 by furin and its role in the regulation of TGF-β signaling. Oncogene. 2010;29(15):2181-2191.
Zhang JM, Hashimoto M, Kawai K, et al. CD109 expression in squamous cell carcinoma of the uterine cervix. Pathol Int. 2005;55(4):165-169. doi:10.1111/j.1440-1827.2005.01807.x
Qi R, Dong F, Liu Q, Murakumo Y, Liu J. CD109 and squamous cell carcinoma. J Transl Med. 2018;16(1):88. doi:10.1186/s12967-018-1461-3
Koh HM, Lee HJ, Kim DC. Usefulness of CD109 expression as a prognostic biomarker in patients with cancer: a systematic review and meta-analysis. Medicine. 2021;100(11):e25006. doi:10.1097/md.0000000000025006
Martin JH, Mohammed R, Delforce SJ, et al. Role of the prorenin receptor in endometrial cancer cell growth. Oncotarget. 2022;13:587-599. doi:10.18632/oncotarget.28224
Delforce SJ, Lumbers ER, Corbisier de Meaultsart C, et al. Expression of renin-angiotensin system (RAS) components in endometrial cancer. Endocr Connect. 2017;6(1):9-19. doi:10.1530/ec-16-0082
Schefe JH, Menk M, Reinemund J, et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res. 2006;99(12):1355-1366. doi:10.1161/01.RES.0000251700.00994.0d
Al-kuraishy HM, Hussien NR, Al-Naimi MS, Al-Buhadily AK, Al-Gareeb AI, Lungnier C. Renin-Angiotensin system and fibrinolytic pathway in COVID-19: one-way skepticism. Biomed Biotechnol Res J. 2020;4(5):33.
Al-kuraishy HM, Al-Gareeb AI, Mostafa-Hedeab G, et al. Effects of β-blockers on the sympathetic and cytokines storms in Covid-19. Front Immunol. 2021;12:749291.
Al-kuraishy HM, Al-Gareeb AI, Abdullah SM, Cruz-Martins N, Batiha GE-S. Case report: hyperbilirubinemia in gilbert syndrome attenuates Covid-19-induced metabolic disturbances. Front Cardiovasc Med. 2021;8:642181.
Alkuraishy HM, Al-Gareeb AI, Waheed HJ. Lipoprotein-associated phospholipase A2 is linked with poor cardio-metabolic profile in patients with ischemic stroke: a study of effects of statins. J Neurosci Rural Pract. 2018;9(4):496-503.
Pringle KG, Delforce SJ, Wang Y, et al. Renin-angiotensin system gene polymorphisms and endometrial cancer. Endocr Connect. 2016;5(3):128-135. doi:10.1530/ec-15-0112
Ronquist G, Rodríguez LA, Ruigómez A, et al. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate. 2004;58(1):50-56. doi:10.1002/pros.10294
Alkazmi L, Al-kuraishy HM, Batiha GE-S, et al. Roxadustat for SARS-CoV-2 infection: old signaling raised new hopes. Drugs R&D. 2022;22:183-186. doi:10.1007/s40268-022-00397-0
Cousin C, Bracquart D, Contrepas A, Corvol P, Muller L, Nguyen G. Soluble form of the (pro)renin receptor generated by intracellular cleavage by furin is secreted in plasma. Hypertension. 2009;53(6):1077-1082. doi:10.1161/hypertensionaha.108.127258
Yoshikawa A, Aizaki Y, Kusano K, et al. The (pro)renin receptor is cleaved by ADAM19 in the Golgi leading to its secretion into extracellular space. Hypertens Res. 2011;34(5):599-605. doi:10.1038/hr.2010.284
Schwarz J, Broder C, Helmstetter A, et al. Short-term TNFα shedding is independent of cytoplasmic phosphorylation or furin cleavage of ADAM17. Biochim Biophys Acta. 2013;1833(12):3355-3367. doi:10.1016/j.bbamcr.2013.10.005
Al-kuraishy HM, Al-Gareeb AI, Waheed HJ, Al-Maiahy TJ. Differential effect of metformin and/or glyburide on apelin serum levels in patients with type 2 diabetes mellitus: concepts and clinical practice. J Adv Pharm Technol Res. 2018;9(3):80-86.
Wang Y, Dai C, Zhou C, et al. Benzotriazole enhances cell invasive potency in endometrial carcinoma through CTBP1-mediated epithelial-mesenchymal transition. Cell Physiol Biochem. 2017;44(6):2357-2367. doi:10.1159/000486123
Xu Q, Ying M, Chen G, et al. ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma. Tumour Biol. 2014;35(8):7575-7586. doi:10.1007/s13277-014-1990-1
Swärd P, Rosengren BE, Jehpsson L, Karlsson MK. Association between circulating furin levels, obesity and pro-inflammatory markers in children. Acta Paediatr. 2021;110(6):1863-1868. doi:10.1111/apa.15774
Babalghith AO, Al-kuraishy HM, Al-Gareeb AI, et al. The potential role of growth differentiation factor 15 in COVID-19: a corollary subjective effect or not? Diagnostics. 2022;12(9):2051.
Yakala GK, Cabrera-Fuentes HA, Crespo-Avilan GE, et al. FURIN inhibition reduces vascular remodeling and atherosclerotic lesion progression in mice. Arterioscler Thromb Vasc Biol. 2019;39(3):387-401. doi:10.1161/atvbaha.118.311903
Batiha GE-S, Olatunde A, El-Mleeh A, et al. Bioactive compounds, pharmacological actions, and pharmacokinetics of wormwood (Artemisia absinthium). Antibiotics. 2020;9(6):353.
Cordova ZM, Grönholm A, Kytölä V, et al. Myeloid cell expressed proprotein convertase FURIN attenuates inflammation. Oncotarget. 2016;7(34):54392-54404. doi:10.18632/oncotarget.11106
Batiha GE-S, Tayebwa DS, Beshbishy AM, N'Da DD, Yokoyama N, Igarashi I. Inhibitory effects of novel ciprofloxacin derivatives on the growth of four Babesia species and Theileria equi. Parasitol Res. 2020;119(9):3061-3073.
Pesu M, Watford WT, Wei L, et al. T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance. Nature. 2008;455(7210):246-250. doi:10.1038/nature07210
Oksanen A, Aittomäki S, Jankovic D, et al. Proprotein convertase FURIN constrains Th2 differentiation and is critical for host resistance against Toxoplasma gondii. J Immunol. 2014;193(11):5470-5479. doi:10.4049/jimmunol.1401629
Lin H, Ah Kioon MD, Lalou C, et al. Protective role of systemic furin in immune response-induced arthritis. Arthritis Rheum. 2012;64(9):2878-2886. doi:10.1002/art.34523
Modugno F, Ness RB, Chen C, Weiss NS. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2840-2847. doi:10.1158/1055-9965.epi-05-0493
Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002;68-69:165-175. doi:10.1016/s0090-6980(02)00029-1
Al-kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE-S. Hippo-YAP signaling and SARS-CoV-2 infection: a new mechanistic pathway. Cell Stress Chaperones. 2023;28(2):121-123. doi:10.1007/s12192-023-01327-y
Batiha GE-S, Alqahtani A, Ojo OA, et al. Biological properties, bioactive constituents, and pharmacokinetics of some Capsicum spp. and capsaicinoids. Int J Mol Sci. 2020;21(15):5179.
Lin Y, Bai L, Chen W, Xu S. The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets. 2010;14(1):45-55. doi:10.1517/14728220903431069
Alomair BM, Al-kuraishy HM, Al-Gareeb AI, et al. Montelukast and acute coronary syndrome: the endowed drug. Pharmaceuticals. 2022;15(9):1147.
Wang X, Wei Z, Tang Z, et al. IL-37bΔ1-45 suppresses the migration and invasion of endometrial cancer cells by targeting the Rac1/NF-κB/MMP2 signal pathway. Lab Invest. 2021;101(6):760-774. doi:10.1038/s41374-021-00544-2
Brant KA, Leikauf GD. Dysregulation of FURIN by prostaglandin-endoperoxide synthase 2 in lung epithelial NCI-H292 cells. Mol Carcinog. 2014;53(3):192-200. doi:10.1002/mc.21963
Yang D, Yao M, Yan Y, et al. Deoxycholic acid upregulates serum golgi protein 73 through activating NF-κB pathway and destroying Golgi structure in liver disease. Biomolecules. 2021;11(2):205. doi:10.3390/biom11020205
Takiuchi T, Blake EA, Matsuo K, Sood AK, Brasky TM. Aspirin use and endometrial cancer risk and survival. Gynecol Oncol. 2018;148(1):222-232. doi:10.1016/j.ygyno.2017.10.026
El-Saber Batiha G, Al-Gareeb AI, Saad HM, Al-kuraishy HM. COVID-19 and corticosteroids: a narrative review. Inflammopharmacology. 2022;30:1189-1205. doi:10.1007/s10787-022-00987-z
Wang Y, Zhao J, Chen X, Zhang F, Li X. Aspirin use and endometrial cancer risk: a meta-analysis and systematic review. Ann Transl Med. 2020;8(7):461. doi:10.21037/atm.2020.03.125
Coppola JM, Bhojani MS, Ross BD, Rehemtulla A. A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia. 2008;10(4):363-370.
Cameron A, Appel J, Houghten RA, Lindberg I. Polyarginines are potent furin inhibitors. J Biol Chem. 2000;275(47):36741-36749.
Marinello PC, Panis C, Silva TN, et al. Oxidative stress and TGF-β1 induction by metformin in MCF-7 and MDA-MB-231 human breast cancer cells are accompanied with the downregulation of genes related to cell proliferation, invasion and metastasis. Pathol Res Pract. 2020;216(10):153135.
Tan BK, Adya R, Chen J, Lehnert H, Cassia LJS, Randeva HS. Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metabol. 2011;96(3):808-816.
Zhuo Z, Wang A, Yu H. Metformin targeting autophagy overcomes progesterone resistance in endometrial carcinoma. Arch Gynecol Obstet. 2016;294:1055-1061.
Mitsuhashi A, Kawasaki Y, Hori M, Fujiwara T, Hanaoka H, Shozu M. Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial). BMJ Open. 2020;10(2):e035416.
Clement NS, Oliver TR, Shiwani H, Saner JR, Mulvaney CA, Atiomo W. Metformin for endometrial hyperplasia: a Cochrane protocol. BMJ Open. 2016;6(8):e013385.
Zhao Y, Sun H, Feng M, et al. Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling. Gynecol Endocrinol. 2018;34(5):428-432.
Guo H, Kong W, Zhang L, et al. Reversal of obesity-driven aggressiveness of endometrial cancer by metformin. Am J Cancer Res. 2019;9(10):2170-2193.
Chae-Kim J, Garg G, Gavrilova-Jordan L, Blake LE, Wu Q, Hayslip CC. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2021;31(12):1499-1505.
Tabrizi AD, Melli MS, Foroughi M, Ghojazadeh M, Bidadi S. Antiproliferative effect of metformin on the endometrium-a clinical trial. Asian Pac J Cancer Prev. 2014;15(23):10067-10070.
Al-kuraishy HM, Al-Gareeb AI, Alexiou A, et al. Pros and cons for statins use and risk of Parkinson's disease: an updated perspective. Pharmacol Res Perspect. 2023;11(2):e01063.
Al-kuraishy HM, Al-Gareeb AI, Hussien NR, Al-Naimi MS, Rasheed HA. Statins an oft-prescribed drug is implicated in peripheral neuropathy: the time to know more. J Pak Med Assoc. 2019;69(8):S108-S112.
Al-kuraishy HM, Al-Gareeb AI. Acylation-stimulating protein is a surrogate biomarker for acute myocardial infarction: role of statins. J Lab Physicians. 2017;9(3):163-169.
Sawaguchi J, Saeki Y, Oda M, et al. The circulating furin-cleaved/mature PCSK9 ratio has a potential prognostic significance in statin-naïve patients with acute ST elevation myocardial infarction. Atheroscler Plus. 2022;50:50-56.
Kuyama N, Kataoka Y, Takegami M, et al. Circulating mature PCSK9 level predicts diminished response to statin therapy. J Am Heart Assoc. 2021;10(11):e019525.
Yu C, Wang G, Liu Q, et al. Host antiviral factors hijack furin to block SARS-CoV-2, ebola virus, and HIV-1 glycoproteins cleavage. Emerging Microbes Infect. 2023;12(1):2164742.
Wang H, Yuan Z, Pavel MA, et al. The role of high cholesterol in age-related COVID19 lethality. bioRxiv. 2020.
Hafizz AMHA, Zin RRM, Aziz NHA, Kampan NC, Shafiee MN. Beyond lipid-lowering: role of statins in endometrial cancer. Mol Biol Rep. 2020;47:8199-8207.
Feng J-L, Dixon-Suen SC, Jordan SJ, Webb PM. Is there sufficient evidence to recommend women diagnosed with endometrial cancer take a statin: results from an Australian record-linkage study. Gynecol Oncol. 2021;161(3):858-863.
Urpilainen E, Ahtikoski A, Arima R, Puistola U, Karihtala P. No association between statin use and the prognosis of endometrial cancer in women with type 2 diabetes. Front Pharmacol. 2021;12:621180.
Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Association between statin use and endometrial cancer survival. Obstet Gynecol. 2015;126(1):144-150.
Desai P, Wallace R, Anderson ML, et al. An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative. Gynecol Oncol. 2018;148(3):540-546.
Akinwunmi B, Vitonis AF, Titus L, Terry KL, Cramer DW. Statin therapy and association with ovarian cancer risk in the New England case control (NEC) study. Int J Cancer. 2019;144(5):991-1000.
Wang Y, Ren F, Song Z, Chen P, Liu S, Ouyang L. Statin use and the risk of ovarian and endometrial cancers: a meta-analysis. BMC Cancer. 2019;19:1-10.
Tuli HS, Aggarwal V, Kaur J, et al. Baicalein: a metabolite with promising antineoplastic activity. Life Sci. 2020;259:118183.
Selvaraj LK, Jeyabalan S, Wong LS, et al. Baicalein prevents stress-induced anxiety behaviors in zebrafish model. Front Pharmacol. 2022;13:4516.
Verma E, Kumar A, Daimary UD, et al. Potential of baicalein in the prevention and treatment of cancer: a scientometric analyses based review. J Funct Foods. 2021;86:104660.
Mcglorthan L, Syed V. Baicalein attenuates endometrial cancer growth by suppressing the ARF6. Cancer Res. 2022;82(12_Supplement):1864.
Li K, Diakite D, Austin J, et al. The flavonoid baicalein negatively regulates progesterone target genes in the uterus in vivo. J Nat Prod. 2021;85(1):237-247.
Kavandi L, Lee LR, Bokhari AA, et al. The Chinese herbs Scutellaria baicalensis and Fritillaria cirrhosa target NFκB to inhibit proliferation of ovarian and endometrial cancer cells. Mol Carcinog. 2015;54(5):368-378.
Dinda B, Dinda M, Dinda S, De UC. An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: insights into molecular mechanisms. Eur J Med Chem. 2023;258:115629.